Advitech Announces Positive Preclinical Results for Wound-Healing Application
QUEBEC CITY, Oct. 10 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced that two
milk-derived protein extracts from its XP-828L technological platform have
demonstrated wound-healing properties in an in vivo study conducted by Dr.
Charles Doillon of the Oncology and Molecular Endocrinology Research Centre at
the Centre Hospitalier de l'Université Laval (CHUL). Dr. Doillon is a
recognized researcher in the field of wound healing and angiogenesis. The
study has demonstrated that both protein extracts could significantly impact
the wound-healing response, especially the formation of regenerated collagen
fibre and its remodelling in wound tissue.